Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,735.00
Bid: 1,735.00
Ask: 1,735.50
Change: 6.50 (0.38%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,737.50
Low: 1,729.00
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: FTSE 100 at three-week high after policy meetings

Thu, 05th Sep 2013 17:03

A host of central-bank policy meetings, a dovish tone from Mario Draghi and the continued improvement in US economic data helped lift stocks higher on Thursday, with the FTSE 100 closing at levels not seen in three weeks.London's benchmark index ended the day up 57.7 points at 6,532.44, its highest level since August 14th when it finished at 6,587.43."European equities are enjoying the continued central-bank activism of low interest rates environment sticking around for the foreseeable future," said Market Strategist Ishaq Siddiqi from ETX Capital.The Bank of Japan, Bank of England and European Central Bank (ECB) all decided to keep interest rates on hold and current stimulus measures in place on Thursday. However, stocks extended gains in the afternoon after ECB President Mario Draghi struck a dovish tone in a press conference following the bank's decision, saying that the Governing Council had even discussed a rate cut at this month's meeting but decided against it. Draghi did however raise his expectations for Eurozone growth for this year.A barrage of US economic data came in better than expected this afternoon, supporting the call for the Federal Reserve to begin tapering asset purchases at its next meeting later this month - jobless claims fell more than forecasts, factory orders declined less than expected and the ISM non-manufacturing index smashed estimates.However, given that the Fed has explicitly said that the labour market is a key factor in its decision, analysts will be watching the August employment report - due out on Friday afternoon - very carefully. Consensus estimates are for a 180,000 increase in non-farm payrolls last month, up from the 162,000 gain in July. The unemployment rate is expected to remain unchanged at 7.4%, though this has already fallen speedily from 7.9% in January.Meanwhile, the G20 meeting which began in St Petersburg today was likely on the back of investors' minds, given that a potential US military strike in Syria is expected to be the hot topic amongst world leaders. Michael Hewson, Senior Market Analyst at CMC Markets, said: "while there may not be much in the way of fireworks we could well see a lot of tension, given the opposing views of the US and Russia, over the rationale for any type of intervention."FTSE 100: M&S leaps after HSBC upgradeHigh Street department store Marks & Spencer surged today after HSBC upgraded the stock from 'neutral' to 'overweight', saying it is the most operationally geared among its peers to play on the UK consumer recovery.Hotels group IHG was also a high riser after UBS raised its rating from 'neutral to 'buy' and added the stock to its 'Most Preferred' list. The Swiss bank highlighted alleviated concerns about pipeline after the company added more rooms in the first half and also pointed to improving growth in China and continued strength in the US.Decent August traffic statistics from airline peers easyJet and IAG over the last 24 hours have helped both stocks rebound today after falling heavily yesterday on the back of a profit warning from Ryanair, Europe's largest low-cost carrier.Banks were also performing well with Lloyds, Standard Chartered, HSBC, RBS and Barclays all registering decent gains. Lloyds was being helped higher by reports that the Treasury could delay the sale of its 39% stake until later this year because of ongoing tensions in the Middle East and the Fed's taper plan.Meanwhile, food groups Tate & Lyle and AB Foods were lower after Credit Suisse highlighted concerns about sugar prices falling sooner and more steeply than expected.Pharmaceuticals group GlaxoSmithKline was also in the red after announcing a setback on its potential new skin-cancer treatment during clinical trials.FTSE 100 - RisersPersimmon (PSN) 1,152.00p +3.69%Marks & Spencer Group (MKS) 494.90p +3.38%ITV (ITV) 174.60p +3.07%Lloyds Banking Group (LLOY) 74.77p +2.95%International Consolidated Airlines Group SA (CDI) (IAG) 299.40p +2.89%Kingfisher (KGF) 405.80p +2.86%GKN (GKN) 346.60p +2.70%Standard Chartered (STAN) 1,472.50p +2.58%Wolseley (WOS) 3,383.00p +2.52%Rolls-Royce Holdings (RR.) 1,147.00p +2.50%FTSE 100 - FallersTate & Lyle (TATE) 799.50p -1.60%Croda International (CRDA) 2,607.00p -1.25%GlaxoSmithKline (GSK) 1,652.50p -0.81%British Sky Broadcasting Group (BSY) 851.50p -0.76%Associated British Foods (ABF) 1,829.00p -0.65%G4S (GFS) 254.40p -0.62%Antofagasta (ANTO) 881.00p -0.56%Bunzl (BNZL) 1,365.00p -0.44%Aggreko (AGK) 1,599.00p -0.37%Admiral Group (ADM) 1,260.00p -0.32%FTSE 250 - RisersICAP (IAP) 400.00p +6.70%Dixons Retail (DXNS) 46.88p +5.92%Supergroup (SGP) 1,227.00p +5.87%Imagination Technologies Group (IMG) 279.30p +5.68%Tullett Prebon (TLPR) 382.40p +5.29%Home Retail Group (HOME) 152.50p +5.03%Halfords Group (HFD) 381.00p +4.01%Rentokil Initial (RTO) 107.50p +3.97%Hochschild Mining (HOC) 277.90p +3.89%Galliford Try (GFRD) 1,015.00p +3.73%FTSE 250 - FallersBumi (BUMI) 213.40p -2.87%Countrywide (CWD) 550.00p -2.65%BH Macro Ltd. EUR Shares (BHME) € 20.62 -2.51%Rank Group (RNK) 153.10p -2.48%Dairy Crest Group (DCG) 490.60p -2.17%Ted Baker (TED) 1,920.00p -2.14%esure Group (ESUR) 228.50p -1.93%International Public Partnerships Ltd. (INPP) 128.60p -1.83%NMC Health (NMC) 323.00p -1.79%Enterprise Inns (ETI) 143.40p -1.71%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.